三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
中国I期伏罗尼布有效提升52周BCVA字母数
中国I期伏罗尼布有效提升52周BCVA字母数
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:177KB
图片尺寸:1112*650
同报告图片
/
4
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
所属报告:
海西新药-2637.HK-港股公司研究报告:仿创双轨推进HXP056有望重塑眼底病用药格局-260702(18页).pdf
打包全文图表
相关数据
美国II期经治患者伏罗尼布减少了抗VEGF注射
fCDnu4TliKsgICAgICAgICAgIHwgNTLlkajlubPlnYfmipdWRUdG5rOo5bCE5qyh5pWwIHwg5qC35pys6YePbiB8CnwtLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS18CnwgWC04MiA1MG1nIFFEICAgIHwgNi43ICAgICAgICAgICAgICAgICAgfCA0MCAgICAgfAp8IFgtODIgMTAwbWcgUUQgICB8IDYuMCAgICAgICAgICAgICAgICAgIHwgMzkgICAgIHwKfCBYLTgyIDIwMG1nIFFEICAgfCA0LjcgICAgICAgICAgICAgICAgICB8IDM5ICAgICB8Cnwg5a6J5oWw5YmCICAgICAgICAgfCA4LjEgICAgICAgICAgICAgICAgICB8IDM5ICAgICB8CgrotYTmlpnmnaXmupDvvJpPcGh0aGFsbW9sb2d577yM5Zu95rOw5rW36YCa6K+B5Yi456CU56m2
收藏
行业数据
2026-07-03
原图定位
查看详情
LUCERNE中至第1年(第48周)BCVA较基线的变
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
收藏
行业数据
2025-07-21
原图定位
查看详情
RHINE中至第2年(第100周)BCVA较基线的变
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
收藏
行业数据
2025-07-21
原图定位
查看详情
YOSEMITE中至第2年(第100周)BCVA较基线的
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
收藏
行业数据
2025-07-21
原图定位
查看详情
RGX-314给药后最佳矫正视力水平(BCVA)和中
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
收藏
行业数据
2025-07-21
原图定位
查看详情
4D-150给药后最佳矫正视力水平(BCVA)和中
fCDlm77ooaggNDY6IDRELTE1MCDnu5noja/lkI7mnIDkvbPnn6vmraPop4blipvmsLTlubPvvIhCQ1ZB77yJ5ZKM5Lit5aSu5a2Q5Zy65Y6a5bqm77yIQ1NU77yJ5Y+Y5YyW5oOF5Ya1IHwKfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCBCZXN0IENvcnJlY3RlZCBWaXN1YWwgQWN1aXR5IHwgQ2VudHJhbCBTdWJmaWVsZCBUaGlja25lc3MgfAp8IFdlZWsgNTI6ICsyLjMgfCBXZWVrIDUyOiAtMTEgfAp8IFdlZWsgNTI6ICsyLjIgfCBXZWVrIDUyOiAtMTMgfAp8IOi1hOaWmeadpea6kO+8mjREIG1vbGVjdWxhciB0aGVyYXBldXRpY3PlrpjnvZHvvIzljY7mupDor4HliLjnoJTnqbbmiYAgfA==
收藏
行业数据
2025-07-21
原图定位
查看详情
TENAYA中至第1年(第48周)BCVA较基线的变
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
收藏
行业数据
2025-07-21
原图定位
查看详情
相比基线平均BCVA变化(假性白内障患者)
fCAgTW9udGggfCAgSUxVVklFTihOPTY2KSB8ICBTaGFtKE49MzQpIHwKfC0tLXwtLS18LS0tfAp8IDAgfCA2LjEoMTMuNSkgfCAyLjkoMTYuNSkgfAp8IDYgfCA2LjEoMTMuNSkgfCAyLjkoMTYuNSkgfAp8IDEyIHwgNi4xKDEzLjUpIHwgMi45KDE2LjUpIHwKfCAxOCB8IDYuMSgxMy41KSB8IDIuOSgxNi41KSB8CnwgMjQgfCA2LjEoMTMuNSkgfCAyLjkoMTYuNSkgfAp8IDMwIHwgNC44KDE3LjgpIHwgMy41KDE2LjEpIHwKfCAzNiB8IDQuOCgxNy44KSB8IDMuNSgxNi4xKSB8CgrotYTmlpnmnaXmupDvvJpBbGltZXJh5YWs5Y+45a6Y572R77yM5aSp6aOO6K+B5Yi456CU56m25omA
收藏
行业数据
2025-06-23
原图定位
查看详情
相比基线平均BCVA变化(有症状的受试者)
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
收藏
行业数据
2025-06-23
原图定位
查看详情
40周最佳矫正视力(BCVA)较基线改善(观测值)
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
收藏
行业数据
2025-04-29
原图定位
查看详情
高度近视患者后巩膜加固术后6个月BCVA变化[眼(%)]
收藏
行业数据
2021-03-08
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
中国 I 期与美国 II 期均展示了伏罗尼布的初步临床疗效,最终停止开发主要系较严重的消化道不良反应以及肝肾毒性。中国 I 期针对 41 例 nAMD 患者(经治比例~50%),52w 时 25/50/75/100mg 剂量组 BCVA 字母数提升分别为 4.3/8.5/12.0/NA 个,整体疗效与阿柏西普基本可比(~10 个)。美国 II期针对 100%经治 nAMD 患者,在通过 2 针 VEGF 注射剂拉平基线后用伏罗尼布做维持,52 周时 50/100/200mg 与安慰剂组平均 VEGF 注射剂补针次数分别为 6.7/6.0/4.7 次 vs 8.1 次,伏罗尼布减少了注射剂注射频次且呈现一定的剂量依赖性疗效。然而,由于较严重的肝肾毒性(20%/28%/23% vs 5%)与消化道不良反应,最终贝达药业停止口服伏罗尼布的开发。我们认为,伏罗尼布的早期数据可初步验证该分子的临床疗效,核心痛点在于体内药代动力学较差,无法同时平衡眼部疗效的提升与全身系统性风险。
行业数据
原图定位
当前图表所属:
海西新药-2637.HK-港股公司研究报告:仿创双轨推进HXP056有望重塑眼底病用药格局-260702(18页).pdf
现有抗VEGF类注射剂产品,核心关注的安全性事件包括眼内炎症与全身系统性风险
经治患者抗VEGF注射剂平均提升0.5-1.5个字母
初治患者抗VEGF注射剂平均提升7-12个字母
眼底类疾病药物迭代方向主要在维持疗效与安全性的同时提升依从性,降低长期给药负担
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》